HZNP News and Press, Horizon Therapeutics Public Limited Company From 04/14/23

2023-04-14 08:47:02 ET Horizon Therapeutics ( NASDAQ: HZNP ) announced Friday that the FDA approved an update to the labeling information of the company's thyroid eye disease (TED) therapy Tepezza related to its indications and usage. Accordingly, the FDA has cleared Tepezza u...

-- Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Indication...

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its first-quarter 2023 financial results on Wednesday, May 3, 2023, prior to the open of the U.S. financial markets. With the pending acquisition by Amgen Inc. and applicable securities laws, Horizon will not be host...

2023-04-13 00:30:00 ET Summary In the Russell 1,000, 33 names are up more than 1,000% since April 12th, 2013. Over the same 10-year period, the S&P 500 tracking ETF is up 211%. The obvious next question is: which stocks will be ten baggers over the next ten years? ...

2023-04-12 18:22:15 ET Amgen's ( NASDAQ: AMGN ) planned $28 billion acquisition of Horizon Therapeutics ( NASDAQ: HZNP ) remains on track to close in the first half of the year. The parties are working expeditiously to respond to the Federal Trade Commission second reque...

2023-04-11 15:20:10 ET Summary Viridian Therapeutics, Inc. has been a profitable investment for me. I am trying to get in again. I will wait for a further fall in the Viridian Therapeutics, Inc. stock price. I bought Viridian Therapeutics, Inc. ( VRDN ) at ar...

2023-04-10 10:10:52 ET Horizon Therapeutics ( NASDAQ: HZNP ) announced Monday that its thyroid eye disease (TED) therapy Tepezza reached the primary endpoint in a Phase 4 trial, indicating a statistically significant reduction in TED symptom proptosis. The randomized placebo-con...

-- At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo -- -- 62% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis at Week 24 (≥ 2 mm) compare...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of Fortune’s 100 Best Companies to Work For ® for the third consecutive year. “We are proud to be named to the Fortune 100 Best Companies to Work For list for the third time,&...